| Members, its important to ADD us to your Email Contact List so you can the crowd and get Stock Market News sent directly to your Inbox and for more assurance, please go to our website www.stockmarketnews.co You can unsubscribe below at any time but you will no longer get Stock Market News.
Revolutionary Biotechnology Company Sets its Sights for New Horizons
| ||
| You don’t even need a prescription to get a piece of this next company. Today’s pick is featured due to its historical trading volume and patterns, certainly, but more so because here is a company on the verge of something big, with all the ingredients for knock-your-socks-off growth!
NUTRA PHARMA CORP. (OTC: NPHC) operates as a biotechnology company specializing in the , licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, , autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the development process. NPHC has announced several impressive benchmarks since the beginning of the year, particularly involving the Company’s moderate to severe relievers -COBROXIN, NYLOXIN and NYLOXIN EXTRA STRENGTH.
| ||
|
NPHC recently announced efforts toward GSA certification for “military strength” relief medication for governmental agencies and announced just a few weeks ago a major marketing campaign with completion of commercials for its independent rep site, www.mynyloxin.com
The company also has its own research and development arm in ReceptoPharm, an innovative biopharmaceutical discovery company developing proprietary therapeutic protein products primarily for the prevention and treatment of viral, autoimmune and neurological diseases in humans.
NPHC ANNOUNCES NEWS!!
| ||
| Nutra Pharma Letter to Shareholders
Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company.
December 4, 2014 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency (), Adrenomyeloneuropathy (AMN), announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
“We have had a very busy year at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “2014 has been a watershed year for the company, bringing in our first significant sales in three years, launching our first new product in over two years () and allowing us to begin the first steps to get back into clinical research on our lead candidates," he continued. "I wanted to take this to update our shareholders and the public on the accomplishments of the year, the status of the Company and briefly outline our goals and expectations for the coming months,” he concluded.
The letter includes some of the following accomplishments made by the Company over the past year: · Began marketing and selling products through MyNyloxin.com Independent Entrepreneurs · Brought all order processing and order fulfillment in-house to the Company's Plantation, Florida facility · Created a marketing campaign for Nyloxin® through the MyNyloxin Distributors that included, print, and · Filed for GSA Certification to Market Nyloxin® and Military Strength Nyloxin® to governmental agencies and the DoD · Rolled out a national campaign that included 30, 60 and 120 second spots (http://www.tinyurl.com/Nyloxinads) · Began weekly promotions on Late Night Health · Began production of Pet , our first new product launch since 2010 · Completed upgrading our facilities and warehouse to accommodate the increased orders and prepare for the delivery of Pet · Completed our Laboratory Recertification to go back to our roots of discovery and clinical development The Shareholder Letter is available on the Company's website at: http://www.nutrapharma.com/Dec2014_shareholder_letter.pdf About Nutra Pharma Corp. Nutra Pharma Corporation operates as a biotechnology company specializing in , licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, , autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (), Adrenomyeloneuropathy (AMN) and . Additionally, the Company markets products for sale for the treatment of under the brand Nyloxin®. For additional information about NutraPharma, visit:
| ||
| SEC Disclaimer This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The publication of this Shareholder Letter should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. # # #
We expect to be compensated $1000.00 to distribute this email by NutraPharma for investor communications services. GENERAL NOTICE AND DISCLAIMER (Please read carefully): We are engaged in the business of advertising and marketing companies for monetary compensation. By viewing or using www.stockmarketnews.co (hereafter referred to as "SMN") you hereby fully agree to our Legal Disclaimer & Disclosure (http://stockmarketnews.co/disclaimer ) and our Policy. This is not a solicitation to buy or sell. This is for entertainment purposes only. Never invest into a stock discussed on our website or the SMN newsletter unless you can afford to lose your entire investment. SMN is not a registered broker dealer or a registered investment adviser. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. Please consult with a certified financial adviser before making any investment decisions. This is sponsored advertising and does not purport to provide an analysis of the featured company's financial position, operations or prospects and is not to be construed as a recommendation or solicitation by SMN, to buy or sell any in any jurisdiction. The information contained herein is based on sources that SMN believes to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. SMN encourages readers and investors to supplement the information in this report with independent research and other professional advice. All information on the featured company is provided by the company profiled, or is available from public sources and SMN makes no representations or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this report are statements of judgment as of the date of publication and are subject to change without further notice and may not necessarily be reprinted in future publications or elsewhere. None of the materials or advertisements herein constitute offers or solicitations to sell securities of the company profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SMN strongly urges you to conduct a complete and independent investigation of the respective companies. SMN does not offer such advice or analysis and SMN further urges you to consult your own independent tax, business, financial and investment advisers. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the company profiled. SMN, its operators, owners, employees, and affiliates may have interests or positions in equity securities of the companies profiled by SMN, some or all of which may have been acquired prior to the dissemination of this report and may increase or decrease these positions at any time. This report may contain forward-looking-statements, which involve risks and uncertainties. Accordingly no assurance can be given that the actual events and results will not be materially different than the anticipated results described in the forward statement. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking-statements made by SMN about the company profiled. If applicable investors are also directed to consider other risks and uncertainties discussed in documents filed by the profiled company with the Securities and Exchange Commission. SMN undertakes no obligation to publicly release the result of any revisions to these forward-looking-statements which may be made to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. Notice of Stock Price Volatility and Movements: Viewers of this newsletter should understand that trading activity and stock prices in many if not all cases tend to increase during the advertisement campaigns of the profiled companies and in many if not all cases tend to decrease thereafter. This tends to create above average volatility and price movements in the profiled company during the advertisement campaign that viewers should take into consideration at all times. Campaigns vary in length, and many are for short periods of time, typically less than a week. Third Advertising /Advertiser: SMN expects to be compensated one-thousand USD from NutraPharma NPHC for investor communications services on NPHC, (hereafter referred to as "this new profile"). SMN receives this compensation as a production budget for advertising efforts and will retain amounts over and above the cost of production, copy-writing services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding this new profile. When compensation for a production budget for its marketing and advertising efforts are retained, SMN will disclose any future compensation if such compensation occurs. In future, SMN will disclose any and all further and future compensation. Some of the services performed have or may include profiling this new profile on the SMN website and issuing opinions concerning this new profile in newsletters. Anyone viewing the SMN website or its newsletters should assume the hiring or affiliates of the hiring own shares of this new profile, which they plan to liquidate. Further, it must be understood that the liquidation of those shares may or may not negatively impact the share price. The third advertiser, has represented that it is not a current shareholder of this new profile and that it does not buy or sell any shares in this new profile during the period that this advertisement is being disseminated. Don’t ever invest based on the info or statements of this newsletter. Do your own research and consult with a licensed professional before investing, only invest what you are prepared to lose. Any statements and opinions given are amateur and biased and should be treated as such. Past performance does not indicate future performance in any way. The performance of all alerts uncompensated and compensated in no way predict the performance of current and/or upcoming alerts. Check the latest SEC filings before investing, and research other information on the risks of investing in microcap companies at www.sec.gov An "alert" is really a promotion. Check disclaimers and you will see this is the case at virtually all penny market newsletters. Many of you assume I make money by getting paid in stock, or something of that nature. This is not the case. I make money by getting paid, not stock. Specifically, wire transfers in USD to my US based bank account. This is the way most newsletters you read operate, and how they make money too. Sometimes I also have issued alerts where I get no payment and do not expect payment, and I just put out the alert at my own discretion. Typically speaking, most alerts I issue are promotions for which I am paid. You can always find this info in the disclaimer below. Furthermore, while I always aggressively state the risks and dangers of trading my alerts, there is a danger that has recently come to my attention. Various individuals in this "industry" have been accused of issuing press releases and/or general company info for various OTC companies that is false, fraudulent, exaggerated, and so on and so forth. This means, even if you do very thorough due diligence on a stock, it is always possible that someone involved with the stock may have put false or exaggerated information out there that could be part of your research. There are only a few cases that I am personally aware of, but how widespread this issue is, is unfortunately unknown. You should keep this in mind when considering taking any trading action. This is further reason, in my personal opinion, why these OTC companies are not suitable for anything resembling a traditional investment. (Long term gains are extremely rare) Here is some information directly from the SEC Website: http://www.sec.gov/investor/pubs/cyberfraud/newsletter.htm DO NOT BUY THIS STOCK WITHOUT DOING YOUR OWN DUE-DILIGENCE!!
| ||
| You have been sent this advertisement through opting in to one or more of our offers, or by becoming one of our customers. We are committed to delivering highly rewarding offers, updates, and promotions. If you no longer wish to see these e-mails, please go here to remove yourself from our subscriber list. Scope Mailings 511 South East 5th Ave #Y1207141 FTL, FL 33301 | ||
Không có nhận xét nào:
Đăng nhận xét